The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …

The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …

Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …

The tyrosine kinase inhibitors (TKIs) directed at sensitizing mutations in the epidermal
growth factor receptor (EGFR) gene represents a critical pillar in non-small cell lung cancer …

Drug resistance inevitably limits the efficacy of all targeted therapies including tyrosine
kinase inhibitors (TKIs). Understanding the biological underpinnings of TKI resistance is key …

The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …

Patients with EGFR-mutant lung cancer derive significant therapeutic benefit from treatment
with EGFR tyrosine kinase inhibitors (TKI). Unfortunately, acquired resistance is an …

The discovery of mutated oncogenes has opened up a new era for the development of more
effective treatments for non-small cell lung cancer patients (NSCLC) harbouring EGFR …

EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …

In the emerging era of targeted therapy for advanced-stage non–small-cell lung cancer, it is
becoming increasingly important to anticipate underlying driver oncogene alterations at the …